

Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

1. (currently amended) A method for treating allergic rhinitis in mammals which comprises intranasally administering a pharmaceutically effective amount of a composition comprising ~~0.01~~ 0.4 – 0.8 % (w/v) olopatadine and ~~0.01—1.0~~ 0.02 – 0.5 % (w/v) of a steroid selected from the group consisting of fluticasone, mometasone, budesonide and beclomethasone, wherein the composition has a pH of 3.5 – 8.0 and a viscosity of 1 – 50 cps.
- 2 & 3. (cancelled).
4. (previously presented) The method of Claim 1 wherein the steroid is fluticasone.
5. (original) The method of Claim 1 wherein the steroid has an average particle size of 2.5 – 5  $\mu\text{m}$ .
6. (original) The method of Claim 1 wherein the steroid has an average particle size of less than 0.8  $\mu\text{m}$ .
7. (original) The method of Claim 6 wherein the steroid has an average particle size of 0.5  $\mu\text{m}$  or less.
8. (original) The method of Claim 1 wherein the composition is an aqueous composition packaged as a nasal spray.
9. (cancelled).
10. (currently amended) A method for treating allergic rhinitis in mammals which comprises intranasally administering a pharmaceutically effective amount of a composition comprising ~~0.01~~ 0.4 – 0.8 % (w/v) olopatadine and 0.02 – 0.5 % (w/v) of a steroid selected from the group consisting of fluticasone, mometasone, budesonide and beclomethasone, wherein the composition has a pH of 3.5 – 8.0 and

a viscosity of 1 – 50 cps., and the composition is an aqueous composition packaged as a nasal spray.